New hope for transplant patients battling severe immune reaction
NCT ID NCT07070674
Summary
This early-stage trial is testing a new oral medication called AC-003 for patients with a severe immune system complication called acute graft-versus-host disease (aGVHD) that can occur after a stem cell transplant. The study aims to find a safe dose and see if the drug can help control the disease in patients whose condition hasn't improved with standard steroid treatment. About 24 adult patients will take the capsules for 28 days while doctors monitor their safety and response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.